Yoda 1 [448947-81-7]

Referencia HY-18723-10mg

embalaje : 10mg

Marca : MedChemExpress


Descripciòn

Yoda 1 is a potent and selective Piezo1 agonist. Yoda 1 activates purified Piezo1 channels. Yoda 1 potently inhibits macropinocytosis induced by epidermal growth factor (EGF). Yoda 1 enhances Ca2+ influx followed by activation of the calcium-activated potassium channel KCa3.1 and inhibition of Rac1 activation[1][2][3].

IC50 & Target

ERK1

 

ERK2

 

In Vitro

Yoda1 (0-6 μM, 5 min) induces the activation of both Akt and ERK1/2, which is not dependent on Piezo1[2].
Yoda1 (1.5 μM, 5 min) inhibits Rac1 activation[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line: human coronary artery endothelial cells (HCAECs)[2], A431 cells[3]
Concentration: 0, 1.5, 3.0, and 6.0 μM
Incubation Time: 5 min
Result: Induced the activation of both Akt and ERK1/2, and increased the phosphorylation levels of both Akt and ERK1/2 in a dose-dependent manner. Inhibited EGF-induced increase in the amount of Rac1-GTP, and inhibited Rac1 activation
Peso molecular

355.27

Fòrmula

C13H8Cl2N4S2

No. CAS
Appearance

Solid

Color

White to light yellow

SMILES

ClC1=C(CSC2=NN=C(C3=NC=CN=C3)S2)C(Cl)=CC=C1

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
Solvente y solubilidad
In Vitro: 

DMSO : 15.62 mg/mL (43.97 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 5 mg/mL (14.07 mM; Need ultrasonic)

Methanol : 2.5 mg/mL (7.04 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8148 mL 14.0738 mL 28.1476 mL
5 mM 0.5630 mL 2.8148 mL 5.6295 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 1.56 mg/mL (4.39 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.56 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.6 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 1.56 mg/mL (4.39 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.56 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.6 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  15% Cremophor EL    85% Saline

    Solubility: 0.62 mg/mL (1.75 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Pureza y Documentación
Referencias

Usted podría estar interesado también en los siguientes productos:



Referencia
Descripción
Cond.
Precio Sin IVA
NB-64-40733-1mg
 1mg 
NB-64-41751-10mg
 10mg 
NB-64-36296-5mg
 5mg